NewGenIvf Group (NIVF) Shares Drop -92% Following Reverse Split and Offering
Key Takeaways
- NewGenIvf Group shares fell roughly 92% over the trailing 30 days, sliding from about $1.21 in early September to near $0.10 per share.
- The selloff was driven by a 1-for-3 reverse stock split and a deeply discounted $1.25 million public offering priced at $0.07 per share.
- NewGenIvf is pivoting beyond its core fertility services business into AI, holding a 13% stake in K25.ai and advancing a cell-sorting (cytometry) platform.
- Four reverse stock splits executed during 2026 underscore ongoing Nasdaq listing-compliance and capital-raising pressure.
- A single-session plunge of roughly 77% followed the company's announcement of the dilutive offering in late September.
NewGenIvf Group (NIVF) Business Overview
NewGenIvf Group Limited provides fertility services from its base in Bangkok, Thailand, with clinics and related operations across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. Its offerings include in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), embryo culture, egg freezing, sperm analysis and sorting, chromosomal screening, and surrogacy support. The company was founded in 2011 and lists on the Nasdaq Capital Market under the ticker NIVF.
More recently, management has framed NIVF as a technology-oriented platform that extends past traditional reproductive care into artificial intelligence and biomedical tools. Key moves include a 13% equity position in K25.ai and progress on Nodexus cell-sorting equipment via an advanced cytometry platform. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. The micro-cap scale and repeated financing activity continue to make the shares highly volatile.
NIVF Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, NIVF shares have declined approximately 92%, moving from a closing level near $1.21 in early September to roughly $0.10. The steepest moves came in late September, when the price fell from about $0.34 to below $0.08 in just a few sessions before recovering modestly.
The quarterly view shows an even sharper drop. On a split-adjusted basis, NIVF traded near $2.60 in late July; by early October the price had reached the $0.10 area, representing a decline of roughly 96% over that interval. The path has been consistently lower, interrupted by abrupt single-day drops linked to corporate actions rather than steady repricing.
Factors Behind the Recent 30-Day Decline
The most immediate driver was the 1-for-3 reverse stock split effective September 1, 2026. Such splits are commonly used to meet exchange minimum-bid rules but do not alter underlying enterprise value and frequently lead to further selling pressure afterward. I’m watching this closely because repeated splits often signal ongoing structural challenges.
The larger catalyst arrived on September 29, when NewGenIvf announced a public offering expected to raise about $1.25 million in gross proceeds through roughly 17.86 million common shares or pre-funded warrants priced at $0.07 each. The terms represented a significant discount, and the stock fell about 77% in one session. Proceeds are intended for the K25.ai investment, debt restructuring, Nodexus machine manufacturing and deployment, plus general working capital. Aegis Capital served as placement agent.
Quarterly Pressures and Longer-Term Context
The broader quarterly weakness aligns with a pattern of multiple reverse splits and equity financings. In 2026 alone, NIVF completed four such splits effective in January, March, July, and September to stay above Nasdaq’s minimum-bid threshold. These actions, together with share issuances and a convertible-note exchange in August, have diluted shareholders and weighed on sentiment.
Management continues to emphasize the K25.ai stake and Nodexus cytometry platform as future growth areas, yet these initiatives have not yet offset the pressures facing a small, capital-constrained business. The late-September financing simply intensified an already downward trajectory.
Key Items to Monitor Going Forward
Investors will want to track whether the offering closes and whether funds are deployed into K25.ai and the Nodexus platform as outlined, and whether those efforts produce tangible revenue or valuation support. Nasdaq compliance stays a focal risk given the history of splits and the sub-$1 share price. Additional capital raises remain a primary concern because further dilution could weigh on the stock. Financial results, debt-restructuring updates, cytometry commercialization progress, and the performance of the K25.ai holding will also matter. Broader appetite for speculative micro-cap and AI-related equities could influence sentiment as well.
Using AI Tools for Volatile Micro-Cap Analysis
When evaluating names like NIVF that move sharply on corporate events, I often turn to Tickeron’s AI-driven resources to cross-check patterns and compare signals across similar securities. One platform that stands out for this type of work is the Trending AI Robots section, which surfaces algorithmic strategies that have performed well in recent market conditions. It gives a concise view of bots with different timeframes and risk profiles so users can explore approaches that fit their own style without any specific security recommendation. From what I see, these tools help put the noise of single-stock volatility into a broader, data-supported context.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
NIVF's Stochastic Oscillator is remaining in oversold zone for 20 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +13.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where NIVF advanced for three days, in 66 of 78 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
NIVF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NIVF as a result. In 38 of 38 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NIVF turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 10 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NIVF moved below its 50-day moving average on August 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NIVF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NIVF entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.031) is normal, around the industry mean (208.195). P/E Ratio (0.001) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.005) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. NIVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement